Tönnies M, Kollmeier J, Bauer T T, Griff S, Kaiser D
Klinik für Thoraxchirurgie, Lungenklinik Heckeshorn, HELIOS Klinikum Emil von Behring, Walterhöferstrasse 11, Berlin.
Pneumologie. 2012 Apr;66(4):218-23. doi: 10.1055/s-0032-1308917. Epub 2012 Apr 4.
The treatment of synchronous solitary lung metastasis in non-small cell lung cancer (NSCLC) remains controversial. Satellite lesions in the same lobe are now classified as T3 which may result in stage IIB (T3N0M0). In contrast, ipsilateral lesions in different lobes are associated with a worse prognosis and classified as T4 tumors (stage IIIA), but operation is usually withheld from these patients. Contralateral lung metastases have been classified more recently as M1a which usually results in a conservative therapy. We analysed survival data of all patients with primary lung tumour and synchronous pulmonary metastasis outside of the tumour-bearing lobe, who underwent surgery.
Between 1997 - 2007 we operated on 57 patients with NSCLC and simultaneous second (solitary) malignant lesions of the lung, outside of the tumour-bearing lobe, after informed consent. Survival was documented and analysed by Kaplan-Meier statistics (log-rank).
The primary tumour was treated in 67 % of cases by lobectomy, in 9 % by pneumonectomy, by bilobectomy in 2 % and in 22 % by segment or wedge resection. The second malignant lesion, and thus potential solitary metastasis, was treated in 83 % by segment or wedge resection. The overall survival of all patients (n = 57) was a median of 82 months (75 - 89 95%CI). In the synchronous second primaries (n = 7) the median survival was 76 months (0.1 to 151 95%CI) and in the synchronous metastases (n = 50) 82 months (95 % CI 75 - 88). This results in a 5-year survival rate of 56 % and 77 %, respectively. The median survival of patients with solitary metastasis, ipsilateral (T4 after UICC7) was 79 months (76 - 82 95 %CI) and with contralateral metastasis (M1a according UICC7) 84 months (60 - 107 95 %CI, p = 0.634).
This analysis shows that patients with solitary pulmonary metastasis (outside of the tumour-bearing lobe) and otherwise operable NSCLC may profit from surgical intervention comprising resection of the primary tumour, lymphadenectomy, and resection of the solitary pulmonary metastasis. Long-term survival can be achieved independent of the localisation of lung metastases (ipsilateral vs. contralateral lung).
非小细胞肺癌(NSCLC)同步性孤立性肺转移的治疗仍存在争议。同一肺叶内的卫星灶现被归类为T3,这可能导致IIB期(T3N0M0)。相比之下,不同肺叶的同侧病灶预后较差,被归类为T4肿瘤(IIIA期),但这些患者通常不进行手术。对侧肺转移最近被归类为M1a,通常采用保守治疗。我们分析了所有接受手术的原发性肺肿瘤并伴有肿瘤所在肺叶以外的同步性肺转移患者的生存数据。
1997年至2007年间,我们在获得知情同意后,对57例NSCLC患者及肿瘤所在肺叶以外的同时性第二(孤立性)肺部恶性病变患者进行了手术。通过Kaplan-Meier统计法(对数秩检验)记录并分析生存率。
67%的病例对原发性肿瘤进行了肺叶切除术,9%进行了全肺切除术,2%进行了双肺叶切除术,22%进行了肺段或楔形切除术。83%的病例对第二个恶性病变,即潜在的孤立性转移灶进行了肺段或楔形切除术。所有患者(n = 57)的总生存期中位数为82个月(75 - 89 95%CI)。同步性第二原发性肿瘤患者(n = 7)的中位生存期为76个月(0.1至151 95%CI),同步性转移患者(n = 50)为82个月(95%CI 75 - 88)。这分别导致5年生存率为56%和77%。孤立性转移患者(UICC7标准下为同侧T4)的中位生存期为79个月(76 - 82 95%CI),对侧转移患者(UICC7标准下为M1a)为84个月(60 - 107 95%CI,p = 0.634)。
该分析表明,伴有孤立性肺转移(肿瘤所在肺叶以外)且其他方面可手术切除的NSCLC患者可能从包括原发性肿瘤切除、淋巴结清扫和孤立性肺转移灶切除的手术干预中获益。无论肺转移位于同侧还是对侧,均可实现长期生存。